^
    Back
    Association details:
    Biomarker:HER-2 overexpression
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:Ogivri (trastuzumab-dkst) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Published date:
    12/12/2018
    Excerpt:
    Ogivri is indicated for the treatment of...in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab...Ogivri should only be used in patients with metastatic or EBC whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.
    Secondary therapy:
    Aromatase inhibitor
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Published date:
    12/12/2018
    Excerpt:
    Ogivri is indicated for the treatment of...Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments…Ogivri should only be used in patients with metastatic or EBC whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.